Alterations of the four driver genes KRAS, CDKN2A, TP53, and SMAD4 are thought critical to the development of pancreatic cancer, in which KRAS mutation and alterations in CDKN2A are considered early events in pancreatic tumorigenesis4. This evidence concerns the gene KRAS and familial pancreatic carcinoma.